J Loftus
Intensive care medicinePhysical therapyGrowth hormone deficiencyHormoneMedicine
What is this?
Publications 35
#1Diane M. Turner-Bowker (Adelphi University)H-Index: 3
#2A. Yaworsky (Adelphi University)H-Index: 3
Last. J Loftus (Pfizer)H-Index: 6
view all 9 authors...
Background Current recombinant human growth hormone (r-hGH) replacement therapy involves long-term daily subcutaneous injections to treat growth hormone deficiency (GHD) in children and adults. Daily r-hGH injections can be burdensome, often resulting in poor treatment compliance. Clinical outcome assessments (COAs) can capture the burden of these injections from the patient (and caregiver) perspective and may demonstrate the benefit of a less-frequent r-hGH injection regimen, which may ultimate...
#1Yanina Jackson (Pfizer)H-Index: 1
#2Ellen M. JanssenH-Index: 6
Last. Mark Lundie (Pfizer)H-Index: 1
view all 9 authors...
ABSTRACTIntroduction: There is a growing trend of using patient preference studies to help incorporate the patient perspective into clinical drug development, care management, and health-care decis...
#1J Loftus (Pfizer)H-Index: 6
#2Cecilia Camacho-Hübner (Pfizer)H-Index: 40
view all 4 authors...
AbstractBackground: Quality of life (QoL) and health economic data are becoming increasingly important factors in healthcare decision making. While there is a wealth of information establishing the benefit of growth hormone (GH) replacement therapy in adults with growth hormone deficiency (aGHD), recent reviews on the QoL and health economic impact of aGHD and the effect of treatment on these factors is limited.Objective: The aim of this article is to summarize the impact of early and sustained ...
#2A. YaworskyH-Index: 3
Last. J LoftusH-Index: 6
view all 7 authors...
#2Roy GomezH-Index: 5
Last. Andrew PalladinoH-Index: 1
view all 11 authors...
#1Nicky Kelepouris (Pfizer)
#2Birol Emir (Pfizer)H-Index: 21
Last. Margaret McDonald (Pfizer)H-Index: 9
view all 6 authors...
#1Michael P. Wajnrajch (Pfizer)H-Index: 10
#2Roy Gomez (Pfizer)H-Index: 5
Last. Andrew Palladino (Pfizer)H-Index: 1
view all 14 authors...
#1Michelle Stewart (Pfizer)H-Index: 10
#2Shannon ShafferH-Index: 1
Last. William R. LenderkingH-Index: 3
view all 7 authors...
Introduction Transthyretin amyloidosis (ATTR amyloidosis), whether manifesting as familial amyloid polyneuropathy (ATTR-PN) or cardiomyopathy (ATTR-CM), is a progressive, debilitating, and often fatal, rare disease requiring significant caregiver support. This study aims to better characterize the burden of disease for ATTR amyloidosis patients and caregivers.
3 CitationsSource
#1M. McNamaraH-Index: 1
#2H. WestheadH-Index: 1
Last. J LoftusH-Index: 6
view all 7 authors...
1 CitationsSource
#1J LoftusH-Index: 6
#2Andreas M. PleilH-Index: 14
Last. Andrew PalladinoH-Index: 1
view all 9 authors...